Rainer Boehm
Directeur/Membre du Conseil chez CELLECTIS S.A.
Fortune : 1 $ au 30/04/2024
Profil
Rainer J.
Boehm is the founder of Rainer Boehm GmbH.
He currently holds multiple positions, including Chairman at Berlin Cures Holding AG, Independent Director at Humanigen, Inc., Independent Director at Cellectis SA, Independent Director at Omega Therapeutics, Inc., and Director at BioCopy AG.
Previously, he served as the Chief Executive Officer & Head-Pharma Division at Novartis Pharma SAS.
He was also an Independent Director at Nordic Nanovector ASA from 2018 to 2022.
From 2005 to 2010, he held the position of Executive Vice President-North America at Novartis Oncology, Inc. Additionally, he served as the Chief Commercial & Medical Affairs Officer at Novartis Pharma Schweiz AG from 2010 to 2017.
Dr. Boehm obtained a doctorate degree from Universität Ulm and an MBA from Schiller International University (France).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
HUMANIGEN INC
0,07% | 11/04/2023 | 84 986 ( 0,07% ) | 1 $ | 31/03/2024 |
CELLECTIS SA
-.--% | 14/02/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
OMEGA THERAPEUTICS, INC.
-.--% | 15/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Rainer Boehm
| Sociétés | Poste | Début |
|---|---|---|
| CELLECTIS S.A. | Directeur/Membre du Conseil | 29/06/2017 |
| HUMANIGEN, INC. | Directeur/Membre du Conseil | 12/02/2018 |
| OMEGA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/09/2022 |
| Rainer Boehm GmbH | Fondateur | - |
| BioCopy AG | Directeur/Membre du Conseil | 01/02/2020 |
Berlin Cures Holding AG
 Berlin Cures Holding AG BiotechnologyHealth Technology Part of Berlin Cures GmbH, Cures Holding AG is a Swiss joint stock company based in Zug, Switzerland. Cures Holding AG specializes in developing a neutralizer for pathogenic functional autoantibodies. The company is home to an unrivaled platform-technology established around BC 007. The company was founded in 2014 by Johannes Müller, and Oliver von Stein has been the CEO of the company since 2023. | Président | - |
Anciens postes connus de Rainer Boehm
| Sociétés | Poste | Fin |
|---|---|---|
| THOR MEDICAL | Directeur/Membre du Conseil | 28/04/2022 |
Novartis Pharma Schweiz AG
 Novartis Pharma Schweiz AG Miscellaneous Commercial ServicesCommercial Services Novartis Pharma Schweiz AG engages in the marketing and distribution of pharmaceutical, chemical, and medical products of the Novartis group. Its products are used in the treatment of diseases in the areas of neurology, immunology, dermatology, ophthalmology, cardiology, and oncology. The company was founded on December 10, 1986 and is headquartered in Rotkreuz, Switzerland. | Directeur Technique/Scientifique/R&D | 01/01/2017 |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01/01/2010 |
| ░░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░ | - |
Formation de Rainer Boehm
| Universität Ulm | Doctorate Degree |
| Schiller International University (France) | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| HUMANIGEN, INC. | Health Technology |
| CELLECTIS S.A. | Health Technology |
| OMEGA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Health Technology |
Novartis Pharma Schweiz AG
Novartis Pharma Schweiz AG Miscellaneous Commercial ServicesCommercial Services Novartis Pharma Schweiz AG engages in the marketing and distribution of pharmaceutical, chemical, and medical products of the Novartis group. Its products are used in the treatment of diseases in the areas of neurology, immunology, dermatology, ophthalmology, cardiology, and oncology. The company was founded on December 10, 1986 and is headquartered in Rotkreuz, Switzerland. | Commercial Services |
Novartis Pharma SAS
 Novartis Pharma SAS Pharmaceuticals: MajorHealth Technology Novartis Pharma SAS wholesales and distributes pharmaceutical products. It offers generic and branded drugs and medicines. The company is headquartered in Rueil-Malmaison, France. | Health Technology |
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
Berlin Cures Holding AG
Berlin Cures Holding AG BiotechnologyHealth Technology Part of Berlin Cures GmbH, Cures Holding AG is a Swiss joint stock company based in Zug, Switzerland. Cures Holding AG specializes in developing a neutralizer for pathogenic functional autoantibodies. The company is home to an unrivaled platform-technology established around BC 007. The company was founded in 2014 by Johannes Müller, and Oliver von Stein has been the CEO of the company since 2023. | Health Technology |
| Rainer Boehm GmbH | |
| BioCopy AG |
